Drug Profile
AEE 788
Alternative Names: AEE788; NVP-AEE788Latest Information Update: 17 Sep 2015
Price :
$50
*
At a glance
- Originator Novartis
- Class Antineoplastics; Purines; Small molecules
- Mechanism of Action Epidermal growth factor receptor antagonists; ERBB 2 receptor antagonists; Protein tyrosine kinase inhibitors; Vascular endothelial growth factor receptor-2 antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Glioblastoma; Solid tumours
Most Recent Events
- 08 Dec 2006 Novartis has discontinued the phase I/II trial of AEE 788 plus everolimus for Glioblastoma in USA
- 08 Dec 2006 Data presented at the 18th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (EORTC-NCI-AACR-2006) added to the adverse events and drug interactions sections
- 26 Jan 2005 Data presented at the 27th Annual San Antonio Breast Cancer Symposium (SABCS-2004) have been added to the Cancer pharmacodynamics section